No Data
Oncternal Therapeutics Reports Q3 2024 Earnings
Express News | Oncternal Therapeutics Inc: Four Oncternal Employees Will Remain in a Part-Time Capacity in Connection With Exploration of Strategic Alternatives
Oncternal Therapeutics Faces Workforce Reduction Challenges: Potential Risks and Implications
Oncternal Therapeutics | 10-Q: Q3 2024 Earnings Report
Oncternal Therapeutics Has Been Granted U.S. Patent Number 12,128,026 Titled "Selective Androgen Receptor Degrader Ligands And Methods Of Use Thereof (For The Treatment Of Prostate Cancer)"
Oncternal Therapeutics Announces Updated Data From Phase 1/2 Study of ONCT-534
No Data
No Data
Gambler007 : There is no response to the news.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP Gambler007 : Not much nope! Watching into AM and PM tomorrow
Gambler007 Trytosaveabit OP : 盘后能否动起来？![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP Gambler007 : Will see? Needs volume
Gambler007 Trytosaveabit OP : 谢谢
View more comments...